The Verve Therapeutics (NASDAQ: VERVE) stock price has risen by 13% today, consolidating an excellent period of growth for the company. Having closed its IPO back in mid-June, the company has skyrocketed in value by 70% in a matter of weeks, leading to heightened investor interest across the board.
This article explains everything you need to know before you invest in Verve Therapeutics after its recent surge. We explain what the company is, what it does, and we also provide our list of the best places to buy and sell VERVE stock online.
Lastly, we give you our VERVE price target to help you understand where we are in the market cycle right now.
For those of you who want to go ahead and buy Verve Therapeutics shares right now, scroll down to the section immediately below where you can find our selection of the best platforms to buy and trade VERVE shares in the UK and elsewhere.
How & where to buy Verve Therapeutics stock online
The best place to invest in VERVE shares, or shares of any other publicly traded company, is a reliable, low-fee stockbroker. These are easy-to-use services that allow you to quickly build a diversified investment portfolio.
Here are our two top picks:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Verve Therapeutics?
It is a genetic medicines company that is listed on the Nasdaq stock exchange under the ticker, VERVE.
Leveraging its expertise, it intends to pioneer a whole new approach to the care of cardiovascular disease. If VERVE achieves its aims, the current archetypal treatment of chronic management will be transformed into single-course, gene-editing medicines.
Should I buy Verve Therapeutics shares?
If you are looking for a high-risk, high-reward company to occupy a small segment of your investment portfolio, Verve could be ideal.
However, medical stocks always carry a degree of risk because every product must progress through lengthy testing imposed by stringent regulatory bodies. This means there are numerous opportunities for things to go wrong along the road to commercialisation.
Right now, there is no analyst coverage of VERVE stock, and the company has not made a great deal of financial information available for easy consumption, so the risks are elevated further. It is for this reason that we cannot currently provide a Verve Therapeutics price target for 2021.